These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9118467)

  • 1. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
    Pruijn FB; van Daalen M; Holford NH; Wilson WR
    Cancer Chemother Pharmacol; 1997; 39(6):541-6. PubMed ID: 9118467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL; Wilson WR; Baguley BC; Ching LM
    Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    Cliffe S; Taylor ML; Rutland M; Baguley BC; Hill RP; Wilson WR
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):373-7. PubMed ID: 8195036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Siim BG; Laux WT; Rutland MD; Palmer BN; Wilson WR
    Cancer Res; 2000 Aug; 60(16):4582-8. PubMed ID: 10969810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
    Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Horsman MR
    Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
    Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
    Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R; Overgaard J; Horsman MR
    Int J Hyperthermia; 2001; 17(6):508-19. PubMed ID: 11719967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
    Liu JJ; Ching LM; Goldthorpe M; Sutherland R; Baguley BC; Kirker JA; McKeage MJ
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):661-9. PubMed ID: 16944150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Wilson WR; Li AE; Cowan DS; Siim BG
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):905-8. PubMed ID: 9845119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.